Press-release for stocks

Prices are updated after-hours

crawled date : 2020 - 12 - 01

save search

Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020
Published: 2020-08-07 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M

Health Technology

| -6.1% | O: -3.29% H: 11.65% C: 10.68%

Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results
Published: 2020-08-12 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M

Health Technology

| -5.66% | O: -0.94% H: 0.0% C: -3.81%
results

Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial
Published: 2020-08-24 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M

Health Technology

| -0.99% | O: -72.75% H: 44.62% C: 24.6%
results phase 3 trial topline

Onconova Therapeutics Announces Election of James J. Marino, JD, MBA as Chairman of the Board of Directors
Published: 2020-08-31 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M

Health Technology

| 265.23% | O: 0.04% H: 0.77% C: -12.12%

Onconova Therapeutics Announces Participation at Upcoming Virtual Events
Published: 2020-09-09 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M

Health Technology

| 382.16% | O: 0.0% H: 7.52% C: 5.01%
therapeutics

Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals
Published: 2020-09-21 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M

Health Technology

| 210.75% | O: 24.3% H: 9.9% C: -9.03%
china biopharma trial phase 3 phase 1 phase 2

Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event
Published: 2020-10-13 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M

Health Technology

| 270.1% | O: 0.67% H: 25.74% C: 23.64%

Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020
Published: 2020-11-05 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M

Health Technology

| 290.93% | O: -0.2% H: 4.97% C: 2.23%
results

Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Published: 2020-11-12 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M

Health Technology

| 242.7% | O: -8.36% H: 0.97% C: -1.08%
results

Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
Published: 2020-11-23 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M

Health Technology

| 269.55% | O: 1.07% H: 0.0% C: -2.82%
drug new drug application

RedBall Acquisition Corp. Completes $575 Million Initial Public Offering
Published: 2020-08-17 (Crawled : 22:15) - globenewswire.com
RBAC | $10.02 0.0%

Finance

| Email alert Add to watchlist
acquisition corp offering acquisition publication

RedBall Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on October 5, 2020
Published: 2020-10-01 (Crawled : 22:15) - globenewswire.com
RBAC | $10.02 0.0%

Finance

| Email alert Add to watchlist
acquisition corp acquisition

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
Published: 2020-05-22 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3

Health Technology

| 363.97% | O: 2.48% H: 5.99% C: 2.68%

Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Published: 2020-05-27 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3

Health Technology

| 343.7% | O: 1.25% H: 0.99% C: -5.18%
sclerosis phase 3 treatment

Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
Published: 2020-06-01 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3

Health Technology

| 376.41% | O: -0.8% H: 2.04% C: -1.22%
disease phase 2b fibrosis cystic fibrosis

Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3

Health Technology

| 362.76% | O: 1.43% H: 2.25% C: 0.64%
treatment phase 2b fibrosis cystic fibrosis

Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
Published: 2020-06-29 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3

Health Technology

| 355.64% | O: 0.64% H: 5.22% C: 0.76%
sclerosis

Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
Published: 2020-07-08 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3

Health Technology

| 342.59% | O: 0.0% H: 0.37% C: -1.12%

Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
Published: 2020-07-29 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3

Health Technology

| 417.32% | O: 1.02% H: 0.72% C: -7.2%

Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
Published: 2020-07-30 (Crawled : 22:15) - globenewswire.com
CRBP | $35.54 -5.83% -6.37% 3

Health Technology

| 451.86% | O: 0.16% H: 7.91% C: 3.41%
results